PedAM
Pediatric Disease Annotations & Medicines
| Disease | conjunctivitis |
| Phenotype | C2607914|allergic rhinitis |
| Sentences | 12 |
| PubMedID- 23706715 | Background: ragweed is an important cause of allergic rhinitis with or without conjunctivitis (ar/c) in north america and elsewhere. |
| PubMedID- 23622121 | Background: in north america and europe, millions of patients experience symptoms of allergic rhinitis with or without conjunctivitis (ar/c) on exposure to ragweed pollen. |
| PubMedID- 25685162 | Background: the effect of sublingual timothy grass immunotherapy tablet 2800 bau (grass slit-t) has been evaluated in three north american trials in adults and children who have allergic rhinitis with or without conjunctivitis (ar/c). |
| PubMedID- 24019844 | Allergic conjunctivitis is closely associated with asthma and allergic rhinitis. |
| PubMedID- PMC4126029 | Patients aged =5 years with a health care professional diagnosis of hay fever, allergic rhinitis, rhino-conjunctivitis, nasal or eye allergies and symptoms or medication for condition in past 12 months were surveyed. |
| PubMedID- 23663473 | Recognition of allergic conjunctivitis in patients with allergic rhinitis. |
| PubMedID- 21790286 | It is indicated for the management of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titer of the specific ige to the grass pollen. |
| PubMedID- 25636947 | Background: the magnitude of effect of sublingual immunotherapy for house dust mite (hdm)-induced allergic rhinitis with or without conjunctivitis is uncertain, partly because there are few well-controlled trials with well-defined doses. |
| PubMedID- 25335122 | Background: 300ir 5-grass pollen sublingual immunotherapy tablets have been approved for the treatment of allergic rhinitis (ar) with or without conjunctivitis in adults and children >5 years with grass pollen allergy. |
| PubMedID- 25640879 | Prevalence of allergic rhinitis, conjunctivitis and/or allergic asthma has increased in the last decades 1,2. allergen immunotherapy (ait), in clinical use for more than 100 yr 3, is accepted on the basis of high-grade evidence as disease modifying treatment for these diseases 4–8. |
| PubMedID- 24468255 | Background: in north america, few studies have evaluated sublingual immunotherapy for allergic rhinitis with or without conjunctivitis (ar/c); pediatric data are sparse. |
| PubMedID- 25535643 (sublingual tablet 2,800 BAU) | The objective is to conduct a systematic review of the beneficial and harmful effects of timothy grass (phleum pratense) standardized allergenic extract (ppae; brand name grastek) 2,800 bau, for the treatment of timothy and related grass pollen-induced allergic rhinitis (ar), with or without conjunctivitis, in adults and children aged five years and older. |
Page: 1